Sumitomo Pharma (4506) Stock Overview
Engages in manufacture, purchase, and sale of pharmaceutical products for medical treatment in Japan, North America, and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
4506 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Sumitomo Pharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥2,142.00 |
| 52 Week High | JP¥2,286.00 |
| 52 Week Low | JP¥500.00 |
| Beta | 0.54 |
| 1 Month Change | 14.06% |
| 3 Month Change | 58.67% |
| 1 Year Change | 264.91% |
| 3 Year Change | 108.37% |
| 5 Year Change | 52.46% |
| Change since IPO | 40.57% |
Recent News & Updates
Recent updates
Results: Sumitomo Pharma Co., Ltd. Beat Earnings Expectations And Analysts Now Have New Forecasts
Aug 04
Sumitomo Pharma Co., Ltd.'s (TSE:4506) Shares Climb 36% But Its Business Is Yet to Catch Up
Jul 30Does Sumitomo Pharma (TSE:4506) Have A Healthy Balance Sheet?
Jul 06Sumitomo Pharma Co., Ltd.'s (TSE:4506) 30% Share Price Surge Not Quite Adding Up
Jun 15We Believe Sumitomo Pharma's (TSE:4506) Earnings Are A Poor Guide For Its Profitability
May 20Sumitomo Pharma Co., Ltd. Just Recorded A 72% EPS Beat: Here's What Analysts Are Forecasting Next
May 15Why Investors Shouldn't Be Surprised By Sumitomo Pharma Co., Ltd.'s (TSE:4506) 26% Share Price Plunge
Apr 09Is Sumitomo Pharma (TSE:4506) Using Debt In A Risky Way?
Mar 19Sumitomo Pharma Co., Ltd. Just Recorded A 593% EPS Beat: Here's What Analysts Are Forecasting Next
Feb 04Sentiment Still Eluding Sumitomo Pharma Co., Ltd. (TSE:4506)
Jan 11Sumitomo Pharma (TSE:4506) Has Debt But No Earnings; Should You Worry?
Nov 25Shareholder Returns
| 4506 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 27.2% | 0.05% | 0.2% |
| 1Y | 264.9% | -7.0% | 19.8% |
Return vs Industry: 4506 exceeded the JP Pharmaceuticals industry which returned -7% over the past year.
Return vs Market: 4506 exceeded the JP Market which returned 19.8% over the past year.
Price Volatility
| 4506 volatility | |
|---|---|
| 4506 Average Weekly Movement | 9.1% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in JP Market | 7.9% |
| 10% least volatile stocks in JP Market | 2.0% |
Stable Share Price: 4506's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4506's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1897 | 3,832 | Toru Kimura | www.sumitomo-pharma.com |
Sumitomo Pharma Co., Ltd. engages in manufacture, purchase, and sale of pharmaceutical products for medical treatment in Japan, North America, and Asia. The company offers therapeutic agents for parkinson’s disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. It also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic.
Sumitomo Pharma Co., Ltd. Fundamentals Summary
| 4506 fundamental statistics | |
|---|---|
| Market cap | JP¥850.99b |
| Earnings (TTM) | JP¥154.72b |
| Revenue (TTM) | JP¥445.21b |
Is 4506 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4506 income statement (TTM) | |
|---|---|
| Revenue | JP¥445.21b |
| Cost of Revenue | JP¥170.81b |
| Gross Profit | JP¥274.39b |
| Other Expenses | JP¥119.67b |
| Earnings | JP¥154.72b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Jan 30, 2026
| Earnings per share (EPS) | 389.45 |
| Gross Margin | 61.63% |
| Net Profit Margin | 34.75% |
| Debt/Equity Ratio | 99.0% |
How did 4506 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/07 18:25 |
| End of Day Share Price | 2025/11/07 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sumitomo Pharma Co., Ltd. is covered by 17 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Ritsuo Watanabe | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Inc |